BNP Paribas Financial Markets
BCAX

BNP Paribas Financial Markets’s Bicara Therapeutics BCAX Stock Holding History

BNP Paribas Financial Markets’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$803K Sell
40,396
-55,505
-58% -$955K ﹤0.01% 3285
2025
Q4 		$1.61M Buy
95,901
+59,385
+163% +$1.01M ﹤0.01% 2779
2025
Q3 		$577K Buy
36,516
+33,348
+1,053% +$373K ﹤0.01% 3470
2025
Q2 		$29.4K Sell
3,168
-18,349
-85% -$219K ﹤0.01% 4451
2025
Q1 		$280K Buy
21,517
+19,687
+1,076% +$261K ﹤0.01% 3526
2024
Q4 		$31.9K Buy
+1,830
New +$38.1K ﹤0.01% 4584

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BNP Paribas Financial Markets's BCAX Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Bicara Therapeutics (BCAX) stake by 58% in Q1 2026, selling an estimated $955K and leaving 40,396 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #3285.

BNP Paribas Financial Markets first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.61M in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • BNP Paribas Financial Markets held 40,396 shares of Bicara Therapeutics worth $803K as of Q1 2026.
  • BNP Paribas Financial Markets sold 55,505 Bicara Therapeutics shares in Q1 2026, an estimated $955K.
  • Bicara Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3285 holding.
  • BNP Paribas Financial Markets first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Bicara Therapeutics position peaked at $1.61M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.